Neurocrine Biosciences-Soleno Therapeutics HSR waiting period expired April 27
Neurocrine Bioscience and Soleno Therapeutics' merger received US regulatory approval following expiration of the Hart-Scott-Rodino waiting period on April 27.Neurocrine Bioscience and Soleno Therapeutics' $2.9 billion merger received US regulatory approval...To view the full article, register now.
Already a subscriber? Click here to view full article